Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2006-04-04
2006-04-04
Lankford, Jr., Leon B. (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S335000, C435S337000, C435S343000, C435S214000, C424S094100, C424S192100, C424S195110, C424S094630
Reexamination Certificate
active
07022521
ABSTRACT:
The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.
REFERENCES:
patent: 3932407 (1976-01-01), Beverung, Jr. et al.
patent: 4088753 (1978-05-01), Parmer
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4206214 (1980-06-01), Harker et al.
patent: RE31617 (1984-06-01), Beverung, Jr. et al.
patent: 4743445 (1988-05-01), Delwiche et al.
patent: 4847276 (1989-07-01), Yarrington
patent: 5185323 (1993-02-01), Gewirtz
patent: 5306709 (1994-04-01), Gewirtz
patent: 5391557 (1995-02-01), Cullinan et al.
patent: 5440020 (1995-08-01), Coller
patent: 5498599 (1996-03-01), Choi et al.
patent: 5506107 (1996-04-01), Cunningham et al.
patent: 5572944 (1996-11-01), Slikkers et al.
patent: 5620960 (1997-04-01), Arnold et al.
patent: 5756083 (1998-05-01), Elliott
patent: 5789539 (1998-08-01), Daly et al.
patent: 5830647 (1998-11-01), Eaton et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5932546 (1999-08-01), Barrett et al.
patent: 6008232 (1999-12-01), Lakshmanan
patent: 6103740 (2000-08-01), Lakshmanan
patent: 6150120 (2000-11-01), Spivak et al.
patent: 6376242 (2002-04-01), Hanson
patent: 6585995 (2003-07-01), Hanson
patent: 2004/0087486 (2004-05-01), Hanson
patent: 0 904 783 (1999-03-01), None
patent: WO 96/25498 (1996-08-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 97/28190 (1997-08-01), None
patent: WO 99/08524 (1999-02-01), None
patent: WO 99/08525 (1999-02-01), None
patent: WO 99/10494 (1999-04-01), None
Wang et al., “Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopietin-induced signaling through induction of SOCS-1”, Blood, Sep. 15, 2000, vol. 96, No. 6, pp. 2093-2099.
Al-Jibouri, L.M. and Najim, R.A., “Effect of dipyridamole on blood glucose and liver cyclic AMP levels and platelet count during endotoxaemia in mice”,Clin. Exp. Pharmacol. Physiol., 15(7):527-32 (1988) ABSTRACT.
Andes, et al., “Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers”,Thromb Haemost., 52(3):325-8 (1984).
Balan, K.K. and Critchley, M., “Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32—a 15 year review”,Br. J. Radiol., 70(839):1169-73 (1997) ABSTRACT.
Balduini, et al., “Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders”,Haematologica, 77(1):40-3 (1992) ABSTRACT.
Barnathan, et al., “Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty”,Circulation, 76(1):125-134 (1987).
Bellucci, et al., “Positive and negative regulation of megakaryocytopoiesis”,C.R. Seances Soc. Biol. Fil., 190(5-6):515-32 (1996) ABSTRACT.
Bunn, H.F., “Pathophysiology of the anemias”,Harrison's Principles of Internal Medicine: Hematology and Onocology, 1514, 1566-67 New York, McGraw-Hill, (1991).
Cazenave, J.P. and Gachet, C., “Anti-platelet drugs: do they affect megakaryocytes?”,Baillieres Clin Haematol, 10(1):163-80 (1):163-80 (1997).
Chen, et al., “Thrombospondin, a negative modulator of megakaryocytopoieses”,J. Lab. Clin. Med., 129(2):231-8 (1997) ABSTRACT.
Cortelazzo, et al., “Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis”,N. Engl. J. Med., 332(17):1132-6 (1995) ABSTRACT.
Dale, et al., “Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand”,Blood, 90(9):3456-3461 (1997).
Davies, et al., “Adverse events reported by postmenopausal women in controlled trials with raloxifene”,Obstetrics&Gynecology, 93(4):558-565 (1999).
De Serres, et al., “Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits:evaluation of the potential for thrombopoietin neutralizing antibody production in man”,Stem Cells, 17:203-209 (1999).
Deng, et al., “A monoclonal antibody cross-reactive with human platelets, megakaryocytes, and common acute lymphocytic leukemia cells”,Blood, 61(4):759-764 (1983).
Gaver, et al., “Disposition of anagrelide, an inhibitor of platelet agregation”,Clin. Pharmacol. Ther., 29(3):381-6 (1981) ABSTRACT.
Gewirtz, et al., “Cell-mediated suppression of megakaryocytopoiesis in acquired amegakaryocytic thrombocytopenic purpura”,Blood, 68(3):619-26 (1986) ABSTRACT.
Glushkov, et al., “Changes in hemostatic system indices during hemosorption in healthy dogs”,Biull Eksp Biol. Med., 94(7):95-8 (1982) ABSTRACT.
Goldberg, et al., “Thrombocytotic suppression of megakaryocyte production from stem cells”,Blood, 49(1):59-69 (1977) ABSTRACT.
Gugliotta, et al., “In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia”,Br. J. Haematol., 71(2):177-81 (1989) ABSTRACT.
Herron, et al., “Inhibition of megakaryocytic colonies in vitro by anagrelide”,Clin. Res., 34(2):459A (1986) ABSTRACT.
Hung, et al., “Focused antithrombotic therapy: novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats”,J. Lab. Clin. Med., 132(6):469-77 (1998) ABSTRACT.
Jones, et al., “Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide”,J. Med. Chem., 30(2):295-303 (1987) ABSTRACT.
Lecomte-Raclet, et al., “New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides”,Blood, 91(8):2772-80 (1998) ABSTRACT.
Ludwig, et al., “Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders”,Cancer Immunol. Immunother., 25(3):266-73 (1987) ABSTRACT.
Mazur, et al., “Analysis of the mechanism of anagrelide—induced thrombocytopenia in humans”,Blood, 79(8):1931-1937 (1992).
Mazzucconi, et al., “Pipobroman therapy of essential thrombocythemia”,Scand J. Haematol., 37(4):306-9 (1986) ABSTRACT.
Mazzucconi, et al., “Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results”,Haematologica, 77(4):315-7 (1992) ABSTRACT.
McCune, et al., “Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations”,Pharmacotherapy, 17(4):822-6 (1197) ABSTRACT.
Meanwell, et al., “Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains”,J. Med. Chem., 35(14):2672-87 (1992) ABSTRACT.
Nagae, S. and Hori, Y., “Immune thrombocytopenia due to Tranilast (Rizaben): detection of drug-dependent platelet-associated IgG”,J. Dermatol., 25(11):706-9 (1998) ABSTRACT.
Negrev, et al., “Influence of nonselective beta-adrenergic impacts on the effects of thrombocytopoietin in mice”,Acta Physiologica et Pharmacologica Bulgaria, 13:1:35-39 (1987).
Ramires, et al., “Effect of ticlopidine and dipyridamole on platelet aggregation and count in patients with chronic stable angina pectoris”,Arq Bras. Cardiol., 56(4):323-7 (1991) ABSTRACT.
Robak, T, et al., “Anagrelide—new antiplatelet drug”,Acta Haematol Pol., 25(4):309-15 (1994) ABSTRACT.
Sato, et al., “Multivariate analysis of risk factors for thrombus formation in University of Tokyo ventricular assist device”,J. Thorac. Cardiovasc. Surg., 106:520-7 (1993).
Scott, et al., “Local delivery of an antithrombin inhi
Davis Ruth A.
Emory University
Lankford , Jr. Leon B.
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and compositions for treating platelet-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating platelet-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating platelet-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563750